NCT03810495已完成1 期
OLANI PK/Safety Study in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Percentage of Participants That Maintain MEC
研究概览
简要总结
This study will examine the pharmacokinetic profile and safety of the O'Neil Long Acting Naltrexone Implant (OLANI) overtime in healthy volunteers. All participants will be treated in an open label manner. No randomization will occur. It is hypothesized that the OLANI will provide sustained therapeutic doses of naltrexone (NTX) for periods up to 6 months via a single subcutaneous application of 2 OLANIs.
详细描述
Naltrexone (NTX) is a nonspecific pure opioid antagonist with a high affinity for the µ-opioid receptor. It blocks the effects of opioids by competitive binding at opiate receptors. NTX is used primarily in the management of opiate and alcohol dependence. It is available in the United States (US) as 2 formulations; a once daily oral formulation (Revia) and a once monthly intramuscular injection (Vivitrol). While NTX is a potent antagonist and efficiently blocks the effects of exogenous opiates such as heroin, the success of NTX for the treatment of opiate dependence has been limited by poor patient compliance. Therefore, the development of a sustained release NTX formulation (in excess of 1 month) would be of great benefit for the treatment of opioid use disorder.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or women between the ages of 18 and 55 years old (inclusive)
- •Without The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) - Substance Related Disorders classification; in sustained remission is not exclusionary
- •Able and willing to comply with the requirements of the protocol
- •Able and willing to provide written informed consent
- •Willing to undergo a minor surgical procedure under local anesthetic to allow for investigational drug administration in the subcutaneous tissue
- •BMI inclusive of 18.5 to 30.0
- •Have an initial weight between 45.3 and 81.6 kilograms (inclusive)
排除标准
- •Positive urine drug screen (UDS) at screening for illicit substances.
- •Is currently on naltrexone medication.
- •Has had a naltrexone implant in the past 24 months.
- •Has received treatment with an extended naltrexone product (e.g. Vivitrol) in the past 12 months.
- •Has a condition which requires treatment with opioid based medication.
- •Has a known hypersensitivity to naltrexone.
- •Has a known hypersensitivity to poly-lactic based materials e.g. biodegradable sutures, surgical implants or previous biodegradable implants.
- •Has a known hypersensitivity to local anesthesia.
- •Is prone to skin rashes, irritation or has a skin condition such as recurrent eczema that is likely to impact the implant site area, or as determined by the evaluating physician.
- •Demonstrates any abnormal skin tissue in the proposed implantation area.
- •Is pregnant or planning to be. Women need to have negative blood pregnancy test at screening. Women need to agree to practice dual contraceptives.
- •Participant is breastfeeding or planning to be.
- •Has a current significant neurological (including cognitive and psychiatric disorders), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological or metabolic disease unless currently controlled and stable with protocol-allowed medication 30 days prior to proposed investigational product administration.
- •Any clinically important abnormal finding as determined by medical history, physical examination, ECG or clinical laboratory tests.
- •Any additional condition(s) that in the investigator's opinion would prohibit the participant from completing the study or would not be in the best interest of the participant.
- •Alanine aminotransferase (ALT) or aspartate transaminase (AST) > 3 times the upper end of the laboratory normal range.
- •Any methadone use 14 days prior to screening, and up to Study Day
- •Current DSM-5 diagnosis of schizophrenia, bipolar, anxiety, or depressive disorder, confirmed by The Mini International Neuropsychiatric Interview (MINI) diagnostic interview assessment, or currently treated with medications for anxiety or depression. Past history (in remission DSM-5 classification) of anxiety or depression is not exclusionary.
- •Any elevated risk for suicide measured using the Columbia Suicide Severity Rating Scale (C-SSRS), endorsing any of the items in the past month (C-SSRS, Lifetime)
- •Is participating or intending to participate in any other clinical trial during the duration of this study.
研究组 & 干预措施
OLANI (naltrexone implant)
Experimental
2 OLANI containing 60% naltrexone (1.8 g total) administered one time subcutaneously
干预措施: naltrexone implant (Drug)
结局指标
主要结局
Percentage of Participants That Maintain MEC
时间窗: up to 540 days or until NTX blood levels become undetectable
Percentage of participants who maintain naltrexone (NTX) blood levels of ≥1.33 ng/mL for ≥180 days
次要结局
- Median Cmax of Naltrexone(pre-dose, at 3, 6, and 12 hours (± 60 minutes) after dosing; 24 and 48 hours (± 2 hours) after dosing; day 4 (± 1 day), day 8 (± 2 days); days 14, 21, 28, 35, 42, 49 and 56 (± 3 days); then every 30 days (± 10 days) up to 540 days)
- AUC of 6β-naltrexol(pre-dose, at 3, 6, and 12 hours (± 60 minutes) after dosing; 24 and 48 hours (± 2 hours) after dosing; day 4 (± 1 day), day 8 (± 2 days); days 14, 21, 28, 35, 42, 49 and 56 (± 3 days); then every 30 days (± 10 days) up to 540 days)
- Tmax of Naltrexone(pre-dose, at 3, 6, and 12 hours (± 60 minutes) after dosing; 24 and 48 hours (± 2 hours) after dosing; day 4 (± 1 day), day 8 (± 2 days); days 14, 21, 28, 35, 42, 49 and 56 (± 3 days); then every 30 days (± 10 days) up to 540 days)
- AUC of Naltrexone(pre-dose, at 3, 6, and 12 hours (± 60 minutes) after dosing; 24 and 48 hours (± 2 hours) after dosing; day 4 (± 1 day), day 8 (± 2 days); days 14, 21, 28, 35, 42, 49 and 56 (± 3 days); then every 30 days (± 10 days) up to 540 days)
- Median Cmax of 6β-naltrexol(pre-dose, at 3, 6, and 12 hours (± 60 minutes) after dosing; 24 and 48 hours (± 2 hours) after dosing; day 4 (± 1 day), day 8 (± 2 days); days 14, 21, 28, 35, 42, 49 and 56 (± 3 days); then every 30 days (± 10 days) up to 540 days)
- Median Tmax of 6β-naltrexol(pre-dose, at 3, 6, and 12 hours (± 60 minutes) after dosing; 24 and 48 hours (± 2 hours) after dosing; day 4 (± 1 day), day 8 (± 2 days); days 14, 21, 28, 35, 42, 49 and 56 (± 3 days); then every 30 days (± 10 days) up to 540 days)
- Time>Minimum Effective Concentration(pre-dose, at 3, 6, and 12 hours (± 60 minutes) after dosing; 24 and 48 hours (± 2 hours) after dosing; day 4 (± 1 day), day 8 (± 2 days); days 14, 21, 28, 35, 42, 49 and 56 (± 3 days); then every 30 days (± 10 days) up to 540 days)
- Incidence of Adverse Events (AEs)(Up to 540 days or until NTX blood levels become undetectable)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent PersonsOpioid Use DisorderNCT05382091Go Medical Industries Pty Ltd250
已完成
1 期
Study of the BIOPIN 6 Naltrexone Implant in Healthy AdultsOpioid Use DisorderNCT06216132Akyso Therapeutics, LLC16
终止
1 期
Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With SchizophreniaSmoking CessationNCT06374290The University of Texas Health Science Center, Houston2
已完成
1 期
The Evaluation of Safety and Tolerance of Commercially Available Naltrexone Administered Daily - Assessment for CBRN OperationsOpioid IntoxicationNCT03879460Timothy Smith15
已完成
4 期
Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and RecoveryOpioid-use DisorderNCT03647774Lars Tanum317